Black Diamond Therapeutics vs Monte Rosa Therapeutics
BDTX and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and GLUE compare
Monte Rosa Therapeutics is the larger company, worth 9.1 times as much as Black Diamond Therapeutics ($794M against $87.3M).
Monte Rosa Therapeutics grew revenue faster over the last twelve months (−61.3% versus −100% for Black Diamond Therapeutics).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | GLUE |
|---|---|---|
| Size and price | ||
| Market cap | $87.3M | $794M |
| Share price | $1.52 | $9.31 |
| Change, 1 year | −67.1% | −35.0% |
| Change, 5 years | −78.6% | −52.4% |
| Beta (5Y) | 2.46 | 1.81 |
| Employees | 21 | 150 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 11.3× |
| P/B | 1.0× (better) | 1.6× |
| FCF yield | – | −22.0% |
| Fair value | – | $8.54 |
| Margin of safety | – | −9.0% |
| Growth | ||
| Revenue growth (TTM) | −100% | −61.3% (better) |
| Net income growth (TTM) | −305% (better) | −725% |
| EPS growth (TTM) | −311% (better) | −660% |
| Profitability | ||
| Operating margin | – | −214% |
| Net margin | – | −186% |
| FCF margin | – | −248% |
| Return on equity | −41.1% | −35.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.92 | 10.32 (better) |
| Altman Z-score | −4.64 | 1.62 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 109% |
| Held by insiders | 9.1% | 11.5% |
| Insider net buying, 12 months | – | −$4.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.8% | 27.6% |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.